Grail (NASDAQ:GRAL) Trading Down 6.6% – Should You Sell?

Grail, Inc. (NASDAQ:GRAL) dropped 6.6% on Friday . The stock traded as low as $42.00 and last traded at $44.60. Approximately 558,219 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 1,429,129 shares. The stock had previously closed at $47.76.

Analyst Upgrades and Downgrades

GRAL has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on Grail in a report on Wednesday, November 27th. They issued an “equal weight” rating and a $16.00 price target on the stock. Wolfe Research initiated coverage on Grail in a report on Friday, November 15th. They issued a “peer perform” rating on the stock.

Grail Stock Down 14.5 %

The firm has a 50 day moving average of $26.32 and a 200-day moving average of $19.06.

Grail (NASDAQ:GRAL) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million during the quarter, compared to the consensus estimate of $35.33 million. On average, analysts expect that Grail, Inc. will post -65.16 EPS for the current year.

Institutional Trading of Grail

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. PVG Asset Management Corp bought a new stake in Grail during the 4th quarter valued at $398,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Grail in the 4th quarter worth $334,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Grail in the 4th quarter worth $1,201,000. Westwood Holdings Group Inc. acquired a new stake in shares of Grail in the 4th quarter worth $1,389,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Grail in the 4th quarter worth $1,020,000.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.